Slendesta™

Slendesta™ is a natural, patented ingredient, an extract of potato protein, standardised in proteinase inhibitors or P12. To date, 12 clinical studies suggest that Slendesta™ is a safe ingredient which promotes satiety and healthy weight loss.

¤ P12 encourages the release of cholecystokinine (CCK), a signalling peptide found naturally in the human body, which induces a feeling of fullness or satiety. Once released, CCK travels via the bloodstream to various organs where it produces a feeling of fullness and satisfaction and thus reduces the urge to eat more. Giving CCK or similar molecules to rats was shown to result in weight loss. Furthermore, rats without CCK receptors became obese and developed related symptoms such as hyperglycaemia or insulin-resistance.

¤ The benefits of P12, the active principle in Slendesta™, have been clinically proven. Taking Slendesta™ leads to statistically significant weight loss as well as reductions in waist and hip measurements.

¤ In diabetic subjects, P12 stimulated the release of CCK and increased the time it took the stomach to empty.

¤ In healthy subjects, P12 reduced energy consumption.

¤ A randomised, placebo-controlled clinical crossover study, involving 45 participants, showed that when Slendesta™ was taken 1 hour before a meal, the feeling of fullness was significantly greater and the urge to eat was reduced. This study also showed that levels of CCK increased, and remained elevated for longer after eating, than was the case in the control group.

¤ Taking P12 was also effective - in a dose-dependent manner - at reducing the glucose peak which normally occurs after a meal. This blood glucose peak causes a rise in insulin which, when occurring on a regular basis, can play a key role in weight gain; taking P12 thus also lowered post-prandial levels of insulin in the blood, an effect that is scientifically recognized to be an important element in weight control.

¤ In a larger randomised, placebo-controlled study of 240 subjects, taking Slendesta™ around 60 minutes before each of two main meals induced significant loss of weight and inches around the waist and hips.

¤ In a 20-week open trial, taking Slendesta™ enabled participants to achieve weight loss of around 5.3 kg by the end of the study, as well as reductions in waist and hip measurements of 16% and 9% respectively, with no side effects.

¤ A 300 to 600 mg dose of Slendesta™ (providing 15 to 30mg P12) taken one hour before each of the day’s two main meals, can thus be considered an effective means of promoting weight loss and controlling weight, and the ideal complement to a low-carb diet and exercise regime.